The US FDA has approved a new biosimilar of Roche and Novartis' blockbuster ophthalmology therapy Lucentis – Coherus BioSciences' Cimerli – which its developer claims is the first to be fully ...

Bausch + Lomb has bought US and Canadian rights to a potential biosimilar competitor to Novartis’ Lucentis from Germany’s Stada, as the blockbuster approaches the end of its patent ...

Novartis AG's revenue and core EPS topped analysts' expectations in Q3. Click here to read more on the analysis of NVS stock ...

Bs: Bevasiranib sodium; CABERNET: A study of Strontium 90 β Radiation With Lucentis to Treat Age-Related Macular Degeneration; CARBON: Combination of Bevasiranib and Lucentis Therapy in Wet AMD ...

"I am thrilled to further strengthen and enrich Ocular's senior leadership team with the appointment of Namrata as Chief ...

The Korea Research Institute of Standards and Science (KRISS) announced that they have developed an advanced disease ...

Background: To identify differences between Ranibizumab and Aflibercept in treatment-naïve patients with neovascular age-related macular degeneration (nvAMD) in a real-life clinical setting ...

Opthea is a clinical-stage biotech firm developing Sozinibercept, targeting VEGF-C and VEGF-D for wet AMD, with Phase 3 ...

Prolia (denosumab) and Evenity (romosozumab) are two monoclonal antibodies used to treat osteoporosis. Lucentis (ranibizumab) and Zaltrap (aflibercept) are two examples used to treat eye problems such ...

Aflibercept (Eylea), bevacizumab (Avastin), brolucizumab (Beovu), and ranibizumab (Lucentis) are anti-VEGF drugs used to treat wet AMD. Another drug, faricimab-svoa (Vabysmo), also stops a second ...

Wet macular degeneration is caused by growth of blood vessels in the macula, causing leakage of blood and fluid. Avastin, Lucentis and Eylea have been used to preserve and improve vision in wet ...

Explore our latest breakthroughs in Wet Age-Related Macular Degeneration Research. Learn more about our innovative pipeline ...